Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.

European journal of cancer (Oxford, England : 1990) - 1 May 2009

Donovan Michael J, Kotsianti Angeliki, Bayer-Zubek Valentina, Verbel David, Teverovskiy Mikhail, Cordon-Cardo Carlos, Costa Jose, Greco F Anthony, Hainsworth John D, Parums Dinah V

Abstract excerpt

PURPOSE: To identify clinical and biometric features associated with overall survival of patients with advanced refractory non-small-cell lung cancer (NSCLC) treated with gefitinib. EXPERIMENTAL DESIGN: One hundred and nine diagnostic NSCLC samples were analysed for EGFR mutation status, EGFR immunohistochemistry, histologic morphometry and quantitative immunofluorescence of 15 markers. Support vector regression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Caspase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclin D1

Share to ErbB Receptors

Share to Gefitinib

Share to Proportional Hazards Models

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 19272767
DOI: 10.1016/j.ejca.2009.02.004

Genes

EGFR
KDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.PMID 19272767Read ↗

Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.Semantic proximity Read ↗

Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data miningSemantic proximity Read ↗

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.Semantic proximity Read ↗

Visualising the Truth: A Composite Evaluation Framework for Score-Based Predictive Models SelectionSemantic proximity Read ↗

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.Semantic proximity Read ↗

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.Semantic proximity Read ↗

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.